Jim Cramer Says Hold Moderna Stock After Phase 3 Trial
Jim Cramer is urging investors to hold Moderna (MRNA) after the biotech company and Merck reported encouraging results from a Phase 3 trial of their personalized mRNA cancer vaccine. Cramer said the results, described in a herald report, point to a potentially significant breakthrough, while also suggesting investors consider taking some profits after Moderna shares … Read more